COST-EFFECTIVENESS ANALYSIS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN CHINA
Author(s)
Zhao M1, Feng W2, Zhang L3, Ke X4, Zhang W4, Xuan J5
1Peking University People's Hospital, Beijing, China, 2First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi'an, China, 3Shanghai Centennial Scientific Company, Shanghai, China, 4Kanghong Pharmaceutical Company, Chengdu, China, 5Sun Yat-Sen University, Guangzhou, China
OBJECTIVES: The objective of this analysis is to evaluate the cost-effectiveness of Conbercept versus Ranibizumab in treating neovascular age-related macular degeneration (AMD), the third leading cause of irreversible blindness worldwide, from China perspective. METHODS: A Markov model, based on best corrected visual acuity (BCVA) letters, was developed to simulate the progression of neovascular AMD among Chinese and to predict the outcomes of Conbercept and Ranibizumab treatment over 1 year. The initial distribution of visual acuity was estimated from MARINA trial. Disease progression was characterized by a series of annual transitions between 5 health states referred to as 90, 75, 60, 45, 30 BCVA letters. A patient’s visual acuity was assumed to either increase by 15 letters, remain the same, decrease by 15 letters or decrease by 30 letters each year. The transition probabilities of Ranibizumab were estimated based on the reported data of EXTEND II trial. The Transition probabilities of Conbercept were extracted from AURORA trial. Utility values were taken from a cross-sectional study. Cost data, including drug cost, administering cost and caregivers cost in different health states, were derived from literatures and direct physician survey. One-way sensitivity analysis was conducted on selected key parameters. RESULTS: One-year total cost was 79,189.94 and 141,291.23 RMB for Conbercept and Ranibizumab respectively; QALY of Conbercept and Ranibizumab was 0.725 and 0.715 respectively. The result suggests a dominant ICER of -6,210,129 RMB/QALY, which indicates that Conbercept, when compared with Ranibizumab in Chinese AMD population, has demonstrated better efficacy and overall lower costs. The one-way sensitivity analysis of key parameters (unit price and annual injection times) didn’t change the conclusion, indicating the robustness of the results. CONCLUSIONS: Compared with Ranibizumab, Conbercept is a cost-effective alternative for the treatment of age-related macular degeneration in Chinese people. Conbercept provides better efficacy with overall lower cost.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PSS34
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Sensory System Disorders